Navigation Links
Hebrew University scientist develop technique for eliminating reblockage of arteries
Date:3/9/2009

Jerusalem, March 9, 2009 An easily implementable technique to avoid reblockage of arteries that have been cleared through angioplasty and stent insertion has been developed by researchers led by Prof. Boris Rubinsky of the Hebrew University of Jerusalem.

Angioplasty is the "gold-standard" treatment for acute myocardial infarction (heart attack), which is the result of abrupt interruption in blood supply to part of the beating heart, usually due to plaque-rupture in an atherosclerotic (hardened) coronary artery.

In angioplasty, a cardiologist dilates the blocked artery by inserting a balloon that is inflated at the point of blockage. This is usually followed by coronary stent implantation to protect the artery and prevent restenosis (reocclusion or reblockage). However, the procedure damages the arterial wall, and therefore restonosis of the dilated artery remains a major clinical problem in cardiology, as well as in other fields of clinical medicine.

Since heart disease remains the leading cause of mortality in the western world, the technique developed by Prof. Rubinsky's research teams offer a highly valuable tool for dealing with cardiology patients. Prof. Rubinsky is the director of the Center for Bioengineering in the Service of Humanity and Society at the Rachel and Selim Benin School of Computer Science and Engineering of the Hebrew University of Jerusalem and a professor in the graduate school at the University of California, Berkeley.

The technique employs the biophysical phenomenon of irreversible electroporation (IRE). IRE destroys cells within seconds, using very short electric field pulses. It causes no damage to structures other than the cells themselves. Compared with other technologies for local destruction of cells and tissue, IRE is simple and does not require special training of the medical team.

In IRE, electrical fields are applied across targeted cells, penetrating the cell membranes, This process leads to cell death, since the electrical fields cause permanent damage to the membranes and the consequent loss of cell stability. The electrical fields damage only the cell membranes, with no collateral damage to other structures in the treated area. While the phenomenon of irreversible electroporation was known for decades, a team led by Prof. Rubinsky developed a new mode of application that affects only selected molecules in tissue, and as a consequence it has become only recently rigorously considered in medicine for various applications of tissue removal.

In an article published March 9 in the journal PLoS ONE, Prof. Rubinsky's team demonstrated that IRE can efficiently, safely and quickly destroy the cells responsible for the restenosis phenomenon in rats. In the study, IRE successfully destroyed almost all of those cells in less than 23 seconds, with no damage to any other structures. Clinical trials on humans for restenosis treatment are planned in the near future.

IRE has been recently used for the first time on human subjects in Melbourne, Australia, for the treatment of prostate, liver and lung tumors. Clinical trials for follow-up through IRE of angioplasty treatments are planned for the near future. Prof. Jay Lavee, head of the heart transplant unit at the Sheba Medical Center, Tel Hashomer, is cooperating with Prof. Rubinsky in development of the IRE technique for heart patients.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. Hebrew University scientists succeed through stem cell therapy in reversing brain birth defects
2. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
3. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
4. RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean
5. Hebrew University research on octopuses sheds light on memory
6. Humans have more distinctive hearing than animals, Hebrew U study shows
7. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
8. Hebrew SeniorLife researcher finds
9. 2 Hebrew University scientists awarded Wolf Prizes
10. NorthShore University HealthSystem Only Hospital in the Region to Use Incisionless Procedure to Reduce Weight Regain
11. New Tel Aviv University research links diabetes to cognitive deterioration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: